

Differential transcript profile of inhibitors with potential anti-venom role in the liver of juvenile and adult *Bothrops jararaca* snake

Cícera Maria Gomes^{1,2}, Karen de Moraes-Zani^{1,2}, Stephen Lu³, Diego de Souza Buarque³, Glória Regina Cardoso Braz^{4,5}, Kathleen Fernandes Grego¹, Aparecida Sadae Tanaka^{6,7}, Anita Mitico Tanaka-Azevedo^{Corresp. 1, 2}

¹ Laboratório de Herpetologia, Instituto Butantan, São Paulo, São Paulo, Brazil

² Interunidades em Biotecnologia, Universidade de São Paulo, São Paulo, São Paulo, Brazil

³ Departamento de Bioquímica, Universidade Federal de São Paulo, São Paulo, São Paulo, Brazil

⁴ Departamento de Bioquímica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil

⁵ Instituto Nacional de Ciência e Tecnologia em Entomologia Molecular, Brazil

⁶ Escola Paulista de Medicina / Departamento de Bioquímica, Universidade Federal de São Paulo, São Paulo, São Paulo, Brazil

⁷ Instituto Nacional de Ciência e Tecnologia em Entomologia Molecular, São Paulo, SP, Brazil

Corresponding Author: Anita Mitico Tanaka-Azevedo

Email address: anita.azevedo@butantan.gov.br

Background. Snakes belonging to the *Bothrops* genus are vastly distributed in Central and South America and are responsible for most cases of reported snake bites in Latin America. The clinical manifestations of the envenomation caused by this genus are due three major activities – proteolytic, hemorrhagic and coagulant – mediated by metalloproteinases, serine proteinases, phospholipases A₂ and other toxic compounds present in snake venom. Interestingly, it was observed that snakes are resistant to the toxic effects of its own and other snake's venoms. This natural immunity may occur due the absence of toxin target or the presence of molecules in the snake plasma able to neutralize such toxins. **Methods.** In order to identify anti-venom molecules, we construct a cDNA library from the liver of *B. jararaca* snakes. Moreover, we analyzed the expression profile of four molecules – the already known anti-hemorrhagic factor Bj46a, one gamma-phospholipase A₂ inhibitor, one inter-alpha inhibitor and one C1 plasma protease inhibitor – in the liver of juvenile and adult snakes by qPCR. **Results.** The results revealed a 30-fold increase of gamma-phospholipase A₂ inhibitor and a minor increase of the inter-alpha inhibitor (5-fold) and of the C1 inhibitor (3-fold) in adults. However, the Bj46a factor seems to be equally transcribed between adults and juveniles. **Discussion.** The results suggest the up-regulation of different inhibitors observed in the adult snakes might be a physiological adaptation to the recurrent contact with their own and even other snake's venoms throughout its lifespan. This is the first comparative analysis of ontogenetic variation of expression profiles of plasmatic proteins with potential anti-venom activities of

the venomous snake *B. jararaca*. Furthermore, the present data contributes to the understanding of the natural resistance described in these snakes.

1 **Differential transcript profile of inhibitors with potential anti-venom role in the liver of**
2 **juvenile and adult *Bothrops jararaca* snake**

3

4 Cícera Maria Gomes^{1,2}, Karen de Moraes-Zani^{1,2}, Stephen Lu³, Diego de Souza Buarque³, Glória
5 Regina Cardoso Braz^{4,5}, Kathleen Fernandes Grego¹, Aparecida Sadae Tanaka^{3,5}, Anita Mitico
6 Tanaka-Azevedo^{1,2}

7

8 ¹Laboratório de Herpetologia, Instituto Butantan São Paulo, Brazil

9 ²Interunidades em Biotecnologia, Universidade de São Paulo, São Paulo, Brazil

10 ³Departamento de Bioquímica, Universidade Federal de São Paulo, São Paulo, Brazil

11 ⁴Departamento de Bioquímica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

12 ⁵Instituto Nacional de Ciência e Tecnologia em Entomologia Molecular

13

14

15 Corresponding authors. The two authors contributed equally.

16 Aparecida Sadae Tanaka, tanaka.bioq@epm.br

17 Anita Mitico Tanaka-Azevedo, anita.azevedo@butantan.gov.br

18

19 **Abstract**

20 **Background.** Snakes belonging to the *Bothrops* genus are vastly distributed in Central and South
21 America and are responsible for most cases of reported snake bites in Latin America. The
22 clinical manifestations of the envenomation caused by this genus are due three major activities –
23 proteolytic, hemorrhagic and coagulant – mediated by metalloproteinases, serine proteinases,
24 phospholipases A₂ and other toxic compounds present in snake venom. Interestingly, it was
25 observed that snakes are resistant to the toxic effects of its own and other snake's venoms. This
26 natural immunity may occur due the absence of toxin target or the presence of molecules in the
27 snake plasma able to neutralize such toxins. **Methods.** In order to identify anti-venom molecules,
28 we construct a cDNA library from the liver of *B. jararaca* snakes. Moreover, we analyzed the
29 expression profile of four molecules – the already known anti-hemorrhagic factor Bj46a, one
30 gamma-phospholipase A₂ inhibitor, one inter-alpha inhibitor and one C1 plasma protease
31 inhibitor – in the liver of juvenile and adult snakes by qPCR. **Results.** The results revealed a 30-
32 fold increase of gamma-phospholipase A₂ inhibitor and a minor increase of the inter-alpha
33 inhibitor (5-fold) and of the C1 inhibitor (3-fold) in adults. However, the Bj46a factor seems to
34 be equally transcribed between adults and juveniles. **Discussion.** The results suggest the up-
35 regulation of different inhibitors observed in the adult snakes might be a physiological adaptation
36 to the recurrent contact with their own and even other snake's venoms throughout its lifespan.
37 This is the first comparative analysis of ontogenetic variation of expression profiles of plasmatic
38 proteins with potential anti-venom activities of the venomous snake *B. jararaca*. Furthermore,
39 the present data contributes to the understanding of the natural resistance described in these
40 snakes.

41 **Keywords:** snake plasma; plasmatic protein; protease inhibitors; anti-venom; *Bothrops jararaca*;
42 gene expression.

43

44 INTRODUCTION

45 The genus *Bothrops* is widely distributed in Central and South America, being the most common
46 genus reported in ophidian accidents (Cidade et al. 2006). In Brazil, the species *Bothrops*
47 *jararaca* (*B. jararaca*) accounts for the majority of the 30,000 cases of envenomation registered
48 annually (Ministério da Saúde 2016), due to its abundance and broad geographical distribution.
49 Clinical manifestations of *B. jararaca* envenomation are due to three main venom activities: 1)
50 proteolytic, resulting in inflammatory edema at the bite site; 2) hemorrhagic, related to
51 endothelial damage and systemic bleeding; and 3) coagulant, responsible for the consumption of
52 coagulation factors and consequent homeostasis disruption (Rosenfeld 1971). These activities are
53 mediated by a number of venom components, such as metalloproteinases, serine proteinases,
54 phospholipases A₂ (PLA₂s), L-amino acid oxidases (LAAOs) and other toxic compounds (Fox et
55 al. 2006; Zelanis et al. 2010). The quantitative and qualitative composition of toxins present in
56 snake venoms may vary according to several factors, such as ontogenetic development (Zelanis
57 et al. 2010), seasonal period (Williams & White 1992), gender (Menezes et al. 2006), diet (Gibbs
58 & Mackessy 2009) and geographical distribution (Alape-Giron et al. 2008).

59 Another intriguing feature of the physiology of snakes is the “natural immunity” towards the
60 toxicity of their own venom and other snake venoms. This resistance may be a result of a
61 mutation in the gene encoding the target of the venom toxin, rendering the target insensitive
62 (Burden et al. 1975; Ohana et al. 1991) and/or due to the presence of proteins that neutralize
63 venom components in the blood of resistant animals (Clark & Voris 1969; Omori-Satoh 1977;
64 Omori-Satoh et al. 1972; Straight et al. 1976). This inter- and intra species resistibility make
65 snake plasma an interesting and rich source of bioactive compounds, since it can be explored for
66 the isolation of proteins that can neutralize the toxic components of snake venoms and can

67 contribute to the development of new approaches for the treatment of ophidic accidents (de
68 Morais-Zani et al. 2013; Lizano et al. 2003).

69 It is believed that studies on the natural resistibility of snakes began with Fontana (1781) who
70 stated that “the venom of the viper is not venomous to its species”, more than 230 years ago.
71 Eighty years after this pioneer report, Guyon (1861) discovered that the natural immunity is not
72 species-specific. Since the observations made by Fontana (1781), a number of “plasma factors”
73 have been identified, isolated and characterized, not only from venomous and non-venomous
74 snakes (Thwin et al. 2000) but also from different animals (Fortes-Dias 2002; Omori-Satoh et al.
75 2000; Thwin & Gopalakrishnakone 1998).

76 In this context, Nahas *et al.* (1973) were the first to identify the presence of a natural inhibitor in
77 the plasma of *B. jararaca* in 1973. Later, Nahas *et al.* (1983) have also described the
78 “inactivating effect” of *B. jararaca* plasma upon the coagulant activity of venom from 27
79 different snake species. Several inhibitors have already been identified in *B. jararaca* plasma and
80 serum. The first molecule isolated from the plasma of this species, to our knowledge, was
81 described by Tanizaki et al. (1991) and has the ability to inhibit the hemorrhagic and caseinolytic
82 activity of *B. jararaca* whole venom. Further, this molecule was reported to also inhibit the
83 venom pro-coagulant activity and lethality (de Oliveira & Tanizaki 1992). Besides, an anti-
84 hemorrhagic factor, Bj46a, a potent inhibitor of metalloproteinases and venom hemorrhagic
85 activity, was also purified from *B. jararaca* serum (Valente et al. 2001). In addition, some PLA₂s
86 inhibitors (PLIs) are identified in *B. jararaca* plasma through proteomic analysis (2D SDS-
87 PAGE and mass spectrometry) (de Morais-Zani et al. 2013). Interestingly, a comparative study
88 of the plasma composition of juvenile and adult *B. jararaca* snakes showed that the inhibitors
89 aforementioned (Bj46a and PLIs) might be present at different levels during ontogenetic

90 development and that this variability can be related to the ontogenetic shift described in its
91 venom (de Moraes-Zani et al. 2013).

92 Although there is an increasing interest in the natural resistance of snakes against venom toxins,
93 the knowledge about snake plasma constitution is still sparse. Therefore, we construct a liver
94 cDNA library from *B. jararaca* adults and compare the expression profile of possible anti-venom
95 molecules between adults and juvenile snakes. The results described herein can open
96 perspectives to the design of new molecules for therapeutic and biotechnological purposes and to
97 the development of new strategies to the management of snake envenomation.

98

99 **METHODS**

100 **Ethics statement**

101 Experimental protocols using animals have been conducted in agreement with the Ethical
102 Principles in Animal Research adopted by the Brazilian College of Animal Experimentation and
103 were approved by the Ethical Committee for Animal Research of Butantan Institute (CEUAIB)
104 under registry No. 794/11 and No. 931/12.

105

106 ***B. jararaca* liver collection**

107 *B. jararaca* specimens were obtained from Herpetology Laboratory of Butantan Institute (São
108 Paulo – Brazil). Eight females were used, five adults and three juveniles, all from São Paulo
109 State, Brazil. Snakes were euthanized by intracoelomic administration of thiopental (90 mg kg⁻¹)
110 and lidocaine hydrochloride (5 mg kg⁻¹). The livers were immediately dissected and stored in
111 liquid nitrogen for cDNA library construction. For qPCR experiments, livers were stored in
112 Trizol (Invitrogen) and kept in -80 °C until use.

113

114 **cDNA library construction and sequencing**

115 The mRNA was isolated from the liver of two *B. jararaca* adults using the RNAeasy Mini Kit
116 (QIAGEN). Thereafter the cDNA library was constructed using the SMART cDNA Library
117 Construction Kit (Clontech) as described by Buarque et al. (2013).

118

119 **Bioinformatics analysis**

120 Bioinformatics analysis was performed as previously described (Karim et al. 2011). The software
121 was written and provided by Dr. José Marcos Ribeiro (NIAID – NIH) in Visual Basic 6.0
122 (Microsoft). The functional annotation of CDS was performed through Blastn and Blastx
123 (Altschul et al. 1990) against several databases (non-redundant protein, refseq-invertebrate,
124 refseq-protozoa, refseq-vertebrate from NCBI and the custom made LEPIDOSAURIA database).
125 The functionally annotated sequences were plotted in a excel spreadsheet (Supplementary data
126 1).

127

128 **Quantitative PCR (qPCR)**

129 Quantitative PCR was performed using three biological samples for each group (juveniles and
130 adults). Total RNA was extracted from the liver of adults and juveniles *B. jararaca* snakes using
131 Trizol (Invitrogen) and quantified using NanoVue equipment (GE Healthcare). Total RNA was
132 treated with 1 Unit of DNase (Fermentas) for 1 h at 37°C. Reactions were stopped by adding
133 EDTA and heating for 10 min at 65°C. cDNA synthesis was performed using the ImProm-II™
134 Reverse Transcription System (Promega) following the manufacturer's guidelines and qPCR was
135 performed according Livak and Schmittgen (2001), using the SYBR® Green PCR Master Mix

136 (Applied Biosystems) in a 7500 Real-Time PCR System (Applied Biosystems). The qPCR
137 reaction was performed using: 1 μ L of 10X diluted cDNA, 6 μ L of SYBR® Green and 150 nM
138 of each specific-primers: B_j46a gene (B_j46a forward and B_j46a reverse), PLI- γ gene (PLI- γ
139 forward and PLI- γ reverse), PLI- α (PLI- α forward and PLI- α reverse), inter-alpha inhibitor
140 (inter-alpha inhibitor forward and inter-alpha inhibitor reverse) and plasma protease C1
141 inhibitor-like (C1- forward and C1- reverse), in a 12 μ L total volume. Primers sequences are
142 listed in supplementary data (*Table 1*). β -actin gene was used as the internal control. The PCR
143 program comprised 40 cycles at 94°C (15 sec) and 60°C (1 min), followed by melt curve
144 generation. Melt curves were analyzed to check the specificity of amplification. Reactions were
145 performed in triplicate (for each biological sample) and all values are represented as the mean \pm
146 standard deviation. An unpaired t test was conducted for statistical analysis, and a significant
147 difference was accepted at $p < 0.05$.

148

149 RESULTS

150 Anti-hemorrhagic factor BJ46a

151 Transcripts encoding to metalloprotease inhibitors were the most abundant in the cDNA library
152 of *B. jararaca* liver (data not shown), including the anti-hemorrhagic factor BJ46a, which
153 presents inhibitory activity against venom metalloproteases. Quantitative analyses obtained by
154 qPCR showed no significant differences between juvenile and adult *B. jararaca* snakes (Figure
155 1A). The partial BJ46a sequence deduced from our cDNA library (amino acids residues 137 to
156 345) was aligned against similar proteins described in other snake species (Figure 2). The
157 deduced amino acid sequence confirms the identity of the transcript and reinforces the similarity
158 among BJ46a and related-inhibitors described in different Viperidae snakes.

159

160 Gamma phospholipase A₂ inhibitor

161 γ -phospholipase A₂ inhibitor (γ -PLI) expression profile analysis by qPCR reveals a up-regulation
162 around 30 fold in adults in relation to juvenile specimens (figure 1B). From our cDNA library, it
163 was possible to deduce the whole inhibitor amino acid sequence (Figure 3). When aligned to the
164 sequence of a previously reported *B. jararaca* γ -PLI, the two sequences differ only by four
165 amino acids residues in the positions 48 (G→A), 200 (F→I), 201 (K→R) and 203 (T→A). Note
166 that the amino acid position numbers correspond to the alignment of several γ -PLI displayed in
167 Figure 3, which showed a high degree of similarity. It is interesting to observe the high incidence
168 of amino acid substitutions found in the C-terminal region, not only between the two γ -PLI
169 described in *B. jararaca*, but among the nine inhibitors aligned, described in three different
170 genera of snakes from Viperidae (*Bothrops* and *Protobothrops*) and Colubridae families
171 (*Elaphe*).

172

173 Inter-alpha inhibitor

174 Transcripts related to the serine protease inhibitor inter-alpha inhibitor presented a 5-fold up-
175 regulation in the liver of adults *B. jararaca* snakes (Figure 1C). The partial amino acid sequence
176 of inter-alpha inhibitor heavy chain (H3-like) deduced from a nucleotide sequence found in our
177 cDNA library, this is the first description in *B. jararaca*. The inter-alpha inhibitor sequence
178 showed similarity to the protein described in several reptile species, such as non-venomous and
179 venomous snakes (*Python bivittatus* and *Protobothrops mucrosquamatus*, respectively), lizards
180 (*Anolis carolinensis* and *Gekko japonicus*) and turtles (*Pelodiscus sinensis* and *Chrysemys picta*
181 *bellii*) (Figure 4).

182

183 Plasma protease C1 inhibitor

184 Transcripts encoding to plasma protease C1 inhibitor showed a 3-fold increased expression in the
185 liver of adult *B. jararaca* in comparison to juvenile individuals (Figure 1D). This is the first
186 report on the presence of transcripts related to C1-inhibitor in *B. jararaca* liver. The C1-inhibitor
187 C-terminal deduced amino acid sequence showed some degree of similarity to the molecule
188 described in the lizard *Anolis carolinensis*, the alligator *Alligator mississippiensis* and in three
189 different species of snakes belonging to Pythonidae, Colubridae and Viperidae families (*Python*
190 *bivittatus*, *Thamnophis sirtalis* and *Protobothrops mucrosquamatus*) (Figure 5). When these
191 sequences were aligned, the high variability in amino acid composition in the C-terminal region
192 of C1-inhibitor among the species above mentioned is remarkable, as shown in figure 5.

193

194 DISCUSSION

195 Although a number of snake venom gland transcriptomes have been characterized and are
196 accessible in databases (for review, see (Brahma et al. 2015)) studies concerning gene expression
197 in other tissues are scarce and only recently became available (Castoe et al. 2011; Schwartz et al.
198 2010). However, none of these studies focused on the quantitative analysis of inhibitors that
199 might be involved on venom neutralization, with comparison of adult and juvenile profile. This
200 comparative analysis may contribute to the elucidation of the physiology and anti-venom
201 mechanisms described in *B. jararaca* plasma.

202 Snake venom metalloproteinases (SVMPs) are the most abundant components in adult and
203 juvenile *B. jararaca* venom proteome and venom gland transcriptome (Zelanis et al. 2012;
204 Zelanis et al. 2016) which displays hemorrhagic activity, as described for jararhagin (Paine et al.
205 1992), HF3 (Assakura et al. 1986), bothropasin (Queiroz et al. 1985) and jararafibrase

206 (Maruyama et al. 1993). Thus, the presence of inhibitory components in snake plasma may take
207 part in the “accidental envenomation”. This is the case of the anti-hemorrhagic factor BJ46a, a
208 glycoprotein isolated from *B. jararaca* plasma that inhibits the hemorrhagic activity of its own
209 venom, as well as the activity of isolated metalloproteinases jararhagin and atrolysin C (Valente
210 et al. 2001).

211 A previous study evaluating the ontogenetic changes in the plasma proteomic profile of *B.*
212 *jararaca* snakes showed that BJ46a is present in a higher relative abundance in the plasma of
213 adult specimens (de Moraes-Zani et al. 2013) suggesting a positive association with the higher
214 hemorrhagic activity described in the venom of adult snakes (Antunes et al. 2010). However, the
215 results presented herein showed no significant differences in BJ46a transcript levels between
216 juvenile and adult *B. jararaca* snakes. These contradictory findings could be explained by the
217 lack of correlation between transcriptome and proteome composition observed in other
218 situations. In this context, Durban et al. (2013) have demonstrated that the ontogenetic changes
219 in venom composition observed in *Crotalus simus simus* are controlled by post-transcriptional
220 mechanisms, since the transcriptome profile of the venom glands of neonate and adult specimens
221 exhibit similar toxin family composition. Nevertheless, the mechanisms underlying the
222 regulation of BJ46a expression in juvenile and adult *B. jararaca* snakes need to be elucidated.
223 Three structural classes of PLIs have been described in snake plasma: (1) α -PLIs, which inhibit
224 specifically acidic PLA₂S from group II (found in the venom of Viperidae snakes), (2) β -PLIs,
225 which inhibit specifically basic PLA₂S from group II, and (3) γ -PLI, which shows inhibitory
226 activity towards group I (from venom of Elapidae, Hydrophiidae and Colubridae snakes) and II
227 PLA₂S (Estevao-Costa et al. 2008; Inoue et al. 1997; Kinkawa et al. 2010). Considering the broad
228 spectrum of pharmacological activities displayed by snake venom PLA₂S, as neurotoxicity,

229 myotoxicity, edema-inducing and anticoagulant activities, the presence of PLIs in the plasma of
230 these animals is of paramount importance.

231 In the present work, we analyzed the transcriptional profile of a γ -PLI in the liver of juvenile and
232 adult *B. jararaca* snakes. qPCR results showed that the levels of transcripts encoding to γ -PLI
233 was 30 fold higher in adult than those observed in juvenile specimens. At a first glance, these are
234 unexpected results, since a previous plasma proteomic analysis indicated that γ -PLI are found in
235 a higher relative abundance in the plasma of juvenile *B. jararaca* (de Moraes-Zani et al. 2013)
236 and the venom of juvenile specimens also displayed higher catalytic PLA₂ activity (Antunes et al.
237 2010). However, a study conducted by Kinkawa et al. (2010) showed that the gene expression of
238 α -, β - and γ -PLIs was induced by the intramuscular injection of venom in the venomous snake
239 *Gloydius brevicaudus*. Therefore, the higher expression levels of γ -PLI in adult *B. jararaca* liver
240 described herein might be the result of the physiological response of the snakes to the repeatedly
241 contact with their own venom during their development.

242 Snake venom serine proteinases (SVSPs) are another important group of toxins that play a
243 central role in the envenomation caused by *B. jararaca* snake. These enzymes affect mainly the
244 hemostatic system, acting on the components of the coagulation cascade and on the fibrinolytic
245 and kallikrein-kinin systems (Serrano 2013). In terms of relative abundance, SVSPs occupy the
246 second position in the venom proteome of this species (Zelanis et al. 2016) Due to the central
247 activity displayed by these toxins, we selected two serine proteinase inhibitors to evaluate the
248 level of their related transcripts in juvenile and adult *B. jararaca* snakes.

249 Inter-alpha inhibitors constitute a family of proteins that acts in the regulation of the
250 inflammatory process and plays a role in wound healing (Kobayashi 2006; Lim 2013). These
251 molecules broadly inhibit serine proteases, decrease pro-inflammatory and enhance anti-

252 inflammatory mediators and block complement activation during systemic inflammation (Fries
253 & Kaczmarczyk 2003; Okroj et al. 2012). These inhibitors can be found in plasma as inter alpha
254 inhibitor, which is composed by two heavy chains (H1 and H2) and one light chain (LC), or as
255 pre-alpha inhibitor, which consists of one heavy (H3) and one light chain (LC) (Fries & Blom
256 2000). In this work, we found that transcripts related to the heavy chain of pre-alpha inhibitor
257 (H3-like) presented a 5-fold up-regulation in the liver of adult *B. jararaca* snakes. It seems
258 plausible that this inhibitor can play a role on the neutralization of the major and minor activities
259 of SVSP, such as disturbance of hemostasis and induction of inflammatory reactions,
260 respectively.

261 Another important plasma serine proteinase inhibitor is C1 inhibitor, a multi-functional molecule
262 that acts inactivating a number of serine proteases in different enzymatic cascades, as
263 complement, coagulation, and fibrinolytic systems (Ghannam et al. 2016). It was hypothesized
264 that this inhibitor could be involved in the neutralization of venom components in case of
265 accidental envenomation. Considering that, in addition to the impact on blood coagulation, *B.*
266 *jararaca* SVSP can activate the complement system. Consequently, generates anaphylatoxins
267 that might play a key role in the inflammatory process and also contribute to the spreading of
268 other venom toxins (Pidde-Queiroz et al. 2010). Therefore, we decided to evaluate the levels of
269 transcripts related to C1 inhibitor in the liver of *B. jararaca* snakes. Results described herein
270 showed that transcripts encoding to this plasma inhibitor showed a 3-fold increase in the liver of
271 adult specimens in comparison to juvenile individuals.

272 The analysis of ontogenetic variation in venom activities of *B. jararaca* showed that the activity
273 of serine proteinases is slightly higher in adult individuals, which could justify the higher

274 expression of serine proteinase inhibitors, as inter-alpha inhibitor and C1 inhibitor, found in the
275 liver of adult snakes.

276 However, it is noteworthy that 3 out of 4 plasmatic proteins studied in the present work are more
277 expressed in the liver of adult snakes. Bearing in mind the results described by Kinkawa et al.
278 (2010), regarding the control of PLIs expression, and taken together the results presented in
279 herein, it is tempting to suggest that the higher expression levels of γ -PLI, inter-alpha inhibitor
280 and C1-inhibitor observed in adult snakes might be a natural physiological response of the
281 snakes to the recurrent contact with their own venom throughout the life. Nevertheless, it is
282 important to emphasize that complementary studies are necessary to support this hypothesis.

283 In summary, this work provides the first comparative analysis of ontogenetic variation of
284 expression profiles of plasmatic proteins with potential anti-venom activities of the venomous
285 snake *B. jararaca*. Our data contributes to the understanding of the natural resistance against
286 “self-enuenomation” described in these snakes and provide new target molecules with
287 biotechnological potential that can be useful for the development of new approaches for the
288 treatment of ophidic accidents.

289

290 **ACKNOWLEDGEMENTS**

291 We are grateful to Ms. Jacilene Barbosa da Silva Monteiro, for technical assistance in DNA
292 sequencing and Real Time PCR experiments (INFAR, Escola Paulista de Medicina,
293 Universidade Federal de São Paulo, Brazil).

294

295 **ADDITIONAL INFORMATION AND DECLARATIONS**

296 **Funding**

297 This work was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo
298 (FAPESP) (Proc. N° 2010/10266-5, 2012/03657-8, 2013/05357-4 and 2014/11108-0), the
299 Conselho Nacional de Desenvolvimento Tecnológico (CNPq) (Proc. No. 308780/2013-2) and the
300 INCT–Entomologia Molecular.

301

302 **Competing Interests**

303 There are no competing interests to declare regarding this manuscript.

304

305 **Author Contributions**

306 • Cícera Maria Gomes performed the experiments, analyzed the data, wrote the manuscript.

307 • Karen de Moraes-Zani wrote the manuscript.

308 • Stephen Lu analyzed the data, wrote the manuscript.

309 • Diego de Souza Buarque performed the experiments.

310 • Glória Regina Cardoso Braz analyzed the data.

311 • Kathleen Fernandes Grego planned the experiments, extracted the liver.

312 • Aparecida Sadae Tanaka planned the experiments, analyzed the data, contributed
313 reagents and other essential materials, wrote the manuscript.

314 • Anita Mitico Tanaka-Azevedo planned the experiments, contributed reagents and other
315 essential materials, wrote the manuscript.

316

317 **REFERENCES**

- 318 Alape-Giron A, Sanz L, Escolano J, Flores-Diaz M, Madrigal M, Sasa M, and Calvete JJ. 2008.
319 Snake venomomics of the lancehead pitviper *Bothrops asper*: geographic, individual, and
320 ontogenetic variations. *J Proteome Res* 7:3556-3571. 10.1021/pr800332p
- 321 Altschul SF, Gish W, Miller W, Myers EW, and Lipman DJ. 1990. Basic local alignment search
322 tool. *J Mol Biol* 215:403-410. 10.1016/S0022-2836(05)80360-2
- 323 Antunes TC, Yamashita KM, Barbaro KC, Saiki M, and Santoro ML. 2010. Comparative
324 analysis of newborn and adult *Bothrops jararaca* snake venoms. *Toxicon* 56:1443-1458.
325 S0041-0101(10)00329-6 [pii] 10.1016/j.toxicon.2010.08.011
- 326 Assakura MT, Reichl AP, and Mandelbaum FR. 1986. Comparison of immunological,
327 biochemical and biophysical properties of three hemorrhagic factors isolated from the
328 venom of *Bothrops jararaca* (jararaca). *Toxicon* 24:943-946. 0041-0101(86)90094-2 [pii]
- 329 Brahma RK, McCleary RJ, Kini RM, and Doley R. 2015. Venom gland transcriptomics for
330 identifying, cataloging, and characterizing venom proteins in snakes. *Toxicon* 93:1-10.
331 10.1016/j.toxicon.2014.10.022 S0041-0101(14)00353-5 [pii]
- 332 Buarque DS, Braz GR, Martins RM, Tanaka-Azevedo AM, Gomes CM, Oliveira FA,
333 Schenkman S, and Tanaka AS. 2013. Differential expression profiles in the midgut of
334 *Triatoma infestans* infected with *Trypanosoma cruzi*. *PLoS One* 8:e61203.
335 10.1371/journal.pone.0061203
- 336 Burden SJ, Hartzell HC, and Yoshikami D. 1975. Acetylcholine receptors at neuromuscular
337 synapses: phylogenetic differences detected by snake alpha-neurotoxins. *Proc Natl Acad*
338 *Sci U S A* 72:3245-3249.

- 339 Castoe TA, Fox SE, Jason de Koning A, Poole AW, Daza JM, Smith EN, Mockler TC, Secor
340 SM, and Pollock DD. 2011. A multi-organ transcriptome resource for the Burmese
341 Python (*Python molurus bivittatus*). *BMC Res Notes* 4:310. 10.1186/1756-0500-4-310
- 342 Cidade DA, Simao TA, Davila AM, Wagner G, Junqueira-de-Azevedo IL, Ho PL, Bon C,
343 Zingali RB, and Albano RM. 2006. *Bothrops jararaca* venom gland transcriptome:
344 analysis of the gene expression pattern. *Toxicon* 48:437-461. S0041-0101(06)00239-X
345 [pii] 10.1016/j.toxicon.2006.07.008
- 346 Clark WC, and Voris HK. 1969. Venom neutralization by rattlesnake serum albumin. *Science*
347 164:1402-1404.
- 348 de Moraes-Zani K, Grego KF, Tanaka AS, and Tanaka-Azevedo AM. 2013. Proteomic Analysis
349 of the Ontogenetic Variability in Plasma Composition of Juvenile and Adult *Bothrops*
350 *jararaca* Snakes. *Int J Proteomics* 2013:135709. 10.1155/2013/135709
- 351 de Oliveira EP, and Tanizaki MM. 1992. Effect of a proteinase inhibitor from the plasma of
352 *Bothrops jararaca* on coagulant and myotoxic activities of *Bothrops* venoms. *Toxicon*
353 30:123-128.
- 354 Durban J, Perez A, Sanz L, Gomez A, Bonilla F, Rodriguez S, Chacon D, Sasa M, Angulo Y,
355 Gutierrez JM, and Calvete JJ. 2013. Integrated "omics" profiling indicates that miRNAs
356 are modulators of the ontogenetic venom composition shift in the Central American
357 rattlesnake, *Crotalus simus simus*. *BMC Genomics* 14:234. 10.1186/1471-2164-14-234
- 358 Estevao-Costa MI, Rocha BC, de Alvarenga Mudado M, Redondo R, Franco GR, and Fortes-
359 Dias CL. 2008. Prospection, structural analysis and phylogenetic relationships of
360 endogenous gamma-phospholipase A(2) inhibitors in Brazilian *Bothrops* snakes

- 361 (Viperidae, Crotalinae). *Toxicon* 52:122-129. S0041-0101(08)00350-4 [pii]
362 10.1016/j.toxicon.2008.04.167
- 363 Fontana F. 1781. Traité sur le vnin de la vipere, sur les poisons americains, sur le laurier-cerise
364 et sur quelques autres poisons vegetaux. On y a joint des observations sur la structure
365 primitive du corps animal. Diffrentes expriences sur la reproduction des nerfs et la
366 description d'un nouveau canal de l'oeil. Florence, 23.
- 367 Fortes-Dias CL. 2002. Endogenous inhibitors of snake venom phospholipases A(2) in the blood
368 plasma of snakes. *Toxicon* 40:481-484. S0041010101002744 [pii]
- 369 Fox JW, Ma L, Nelson K, Sherman NE, and Serrano SM. 2006. Comparison of indirect and
370 direct approaches using ion-trap and Fourier transform ion cyclotron resonance mass
371 spectrometry for exploring viperid venom proteomes. *Toxicon* 47:700-714.
- 372 Fries E, and Blom AM. 2000. Bikunin--not just a plasma proteinase inhibitor. *Int J Biochem Cell*
373 *Biol* 32:125-137.
- 374 Fries E, and Kaczmarczyk A. 2003. Inter-alpha-inhibitor, hyaluronan and inflammation. *Acta*
375 *Biochim Pol* 50:735-742. 035003735
- 376 Ghannam A, Sellier P, Fain O, Martin L, Ponard D, and Drouet C. 2016. C1 Inhibitor as a
377 glycoprotein: The influence of polysaccharides on its function and autoantibody target.
378 *Mol Immunol* 71:161-165. 10.1016/j.molimm.2016.02.007 S0161-5890(16)30021-9 [pii]
- 379 Gibbs HL, and Mackessy SP. 2009. Functional basis of a molecular adaptation: prey-specific
380 toxic effects of venom from *Sistrurus rattlesnakes*. *Toxicon* 53:672-679.
381 10.1016/j.toxicon.2009.01.034
- 382 Guyon J. 1861. Le venin des Serpents exerce-t-ilsur eux-mmes l'action qu'il exerce sur d'autres
383 animaux. *C R Ac des Sc LIII*:12.

- 384 Inoue S, Shimada A, Ohkura N, Ikeda K, Samejima Y, Omori-Satoh T, and Hayashi K. 1997.
385 Specificity of two types of phospholipase A2 inhibitors from the plasma of venomous
386 snakes. *Biochem Mol Biol Int* 41:529-537.
- 387 Karim S, Singh P, and Ribeiro JM. 2011. A deep insight into the sialotranscriptome of the gulf
388 coast tick, *Amblyomma maculatum*. *PLoS One* 6:e28525. 10.1371/journal.pone.0028525
- 389 Kinkawa K, Shirai R, Watanabe S, Toriba M, Hayashi K, Ikeda K, and Inoue S. 2010. Up-
390 regulation of the expressions of phospholipase A2 inhibitors in the liver of a venomous
391 snake by its own venom phospholipase A2. *Biochem Biophys Res Commun* 395:377-381.
392 10.1016/j.bbrc.2010.04.024
- 393 Kobayashi H. 2006. Endogenous anti-inflammatory substances, inter-alpha-inhibitor and
394 bikunin. *Biol Chem* 387:1545-1549. 10.1515/BC.2006.192
- 395 Lim YP. 2013. ProThera Biologics, Inc.: a novel immunomodulator and biomarker for life-
396 threatening diseases. *R I Med J (2013)* 96:16-18.
- 397 Livak KJ, and Schmittgen TD. 2001. Analysis of relative gene expression data using real-time
398 quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25:402-408.
399 10.1006/meth.2001.1262 S1046-2023(01)91262-9 [pii]
- 400 Lizano S, Domont G, and Perales J. 2003. Natural phospholipase A(2) myotoxin inhibitor
401 proteins from snakes, mammals and plants. *Toxicon* 42:963-977.
402 10.1016/j.toxicon.2003.11.007 S0041010103003337 [pii]
- 403 Maruyama M, Tanigawa M, Sugiki M, Yoshida E, and Mihara H. 1993. Purification and
404 characterization of low molecular weight fibrinolytic/hemorrhagic enzymes from snake
405 (*Bothrops jararaca*) venom. *Enzyme Protein* 47:124-135.

- 406 Menezes MC, Furtado MF, Travaglia-Cardoso SR, Camargo AC, and Serrano SM. 2006. Sex-
407 based individual variation of snake venom proteome among eighteen *Bothrops jararaca*
408 siblings. *Toxicon* 47:304-312. S0041-0101(05)00399-5 [pii]
409 10.1016/j.toxicon.2005.11.007
- 410 Ministério da Saúde. 2016. Casos de acidentes por serpentes. Brasil, Grandes Regiões e
411 Unidades Federais. 2000 a 2015. Brasil.
- 412 Nahas L, Betti F, Kamiguti AS, and Sato H. 1973. Blood coagulation inhibitor in a snake plasma
413 (*Bothrops jararaca*). *Thrombosis et Diathesis Haemorrhagica* 30:106-113.
- 414 Nahas L, Kamiguti AS, Sousa e Silva MC, Ribeiro de Barros MA, and Morena P. 1983. The
415 inactivating effect of *Bothrops jararaca* and *Waglerophis merremii* snake plasma on the
416 coagulant activity of various snake venoms. *Toxicon* 21:239-246.
- 417 Ohana B, Fraenkel Y, Navon G, and Gershoni JM. 1991. Molecular dissection of cholinergic
418 binding sites: how do snakes escape the effect of their own toxins? *Biochem Biophys Res*
419 *Commun* 179:648-654. 0006-291X(91)91421-8 [pii]
- 420 Okroj M, Holmquist E, Sjolander J, Corrales L, Saxne T, Wisniewski HG, and Blom AM. 2012.
421 Heavy chains of inter alpha inhibitor (IalphaI) inhibit the human complement system at
422 early stages of the cascade. *J Biol Chem* 287:20100-20110. 10.1074/jbc.M111.324913
423 M111.324913 [pii]
- 424 Omori-Satoh T. 1977. Antihemorrhagic factor as a proteinase inhibitor isolated from the serum
425 of *Trimeresurus flavoviridis*. *Biochim Biophys Acta* 495:93-98.
- 426 Omori-Satoh T, Sadahiro S, Ohsaka A, and Murata R. 1972. Purification and characterization of
427 an antihemorrhagic factor in the serum of *Trimeresurus flavoviridis*, a crotalid. *Biochim*
428 *Biophys Acta* 285:414-426.

- 429 Omori-Satoh T, Yamakawa Y, and Mebs D. 2000. The antihemorrhagic factor, erinacin, from
430 the European hedgehog (*Erinaceus europaeus*), a metalloprotease inhibitor of large
431 molecular size possessing ficolin/opsonin P35 lectin domains. *Toxicon* 38:1561-1580.
432 S0041-0101(00)00090-8 [pii]
- 433 Paine MJ, Desmond HP, Theakston RD, and Crampton JM. 1992. Purification, cloning, and
434 molecular characterization of a high molecular weight hemorrhagic metalloprotease,
435 jararhagin, from *Bothrops jararaca* venom. Insights into the disintegrin gene family. *J*
436 *Biol Chem* 267:22869-22876.
- 437 Pidde-Queiroz G, Furtado Mde F, Filgueiras CF, Pessoa LA, Spadafora-Ferreira M, van den
438 Berg CW, and Tambourgi DV. 2010. Human complement activation and anaphylatoxins
439 generation induced by snake venom toxins from *Bothrops* genus. *Mol Immunol* 47:2537-
440 2544. 10.1016/j.molimm.2010.07.003 S0161-5890(10)00504-3 [pii]
- 441 Queiroz LS, Santo Neto H, Assakura MT, Reichl AP, and Mandelbaum FR. 1985. Pathological
442 changes in muscle caused by haemorrhagic and proteolytic factors from *Bothrops*
443 *jararaca* snake venom. *Toxicon* 23:341-345.
- 444 Rosenfeld G. 1971. *Symptomatology, pathology and treatment of snake bites in South America*.
445 New York.
- 446 Schwartz TS, Tae H, Yang Y, Mockaitis K, Van Hemert JL, Proulx SR, Choi JH, and
447 Bronikowski AM. 2010. A garter snake transcriptome: pyrosequencing, de novo
448 assembly, and sex-specific differences. *BMC Genomics* 11:694. 10.1186/1471-2164-11-
449 694
- 450 Serrano SM. 2013. The long road of research on snake venom serine proteinases. *Toxicon* 62:19-
451 26. 10.1016/j.toxicon.2012.09.003 S0041-0101(12)00746-5 [pii]


- 452 Straight R, Glenn JL, and Snyder CC. 1976. Antivenom activity of rattlesnake blood plasma.
453 *Nature* 261:259-260.
- 454 Tanizaki MM, Kawasaki H, Suzuki K, and Mandelbaum FR. 1991. Purification of a proteinase
455 inhibitor from the plasma of *Bothrops jararaca* (jararaca). *Toxicon* 29:673-681.
- 456 Thwin MM, and Gopalakrishnakone P. 1998. Snake envenomation and protective natural
457 endogenous proteins: a mini review of the recent developments (1991-1997). *Toxicon*
458 36:1471-1482. S0041-0101(98)00137-8 [pii]
- 459 Thwin MM, Gopalakrishnakone P, Kini RM, Armugam A, and Jeyaseelan K. 2000.
460 Recombinant antitoxic and antiinflammatory factor from the nonvenomous snake *Python*
461 *reticulatus*: phospholipase A2 inhibition and venom neutralizing potential. *Biochemistry*
462 39:9604-9611. bi000395z [pii]
- 463 Valente RH, Dragulev B, Perales J, Fox JW, and Domont GB. 2001. BJ46a, a snake venom
464 metalloproteinase inhibitor. Isolation, characterization, cloning and insights into its
465 mechanism of action. *Eur J Biochem* 268:3042-3052.
- 466 Williams V, and White J. 1992. Variation in the composition of the venom from a single
467 specimen of *Pseudonaja textilis* (common brown snake) over one year. *Toxicon* 30:202-
468 206.
- 469 Zelanis A, Andrade-Silva D, Rocha MM, Furtado MF, Serrano SM, Junqueira-de-Azevedo IL,
470 and Ho PL. 2012. A transcriptomic view of the proteome variability of newborn and adult
471 *Bothrops jararaca* snake venoms. *PLoS Negl Trop Dis* 6:e1554.
472 10.1371/journal.pntd.0001554 PNTD-D-11-01075 [pii]
- 473 Zelanis A, Menezes MC, Kitano ES, Liberato T, Tashima AK, Pinto AF, Sherman NE, Ho PL,
474 Fox JW, and Serrano SM. 2016. Proteomic identification of gender molecular markers in

475 *Bothrops jararaca* venom. *J Proteomics* 139:26-37. 10.1016/j.jprot.2016.02.030 S1874-
476 3919(16)30051-3 [pii]

477 Zelanis A, Tashima AK, Rocha MM, Furtado MF, Camargo AC, Ho PL, and Serrano SM. 2010.
478 Analysis of the ontogenetic variation in the venom proteome/peptidome of *Bothrops*
479 *jararaca* reveals different strategies to deal with prey. *J Proteome Res* 9:2278-2291.
480 10.1021/pr901027r

481

482




483

484 **Figure 1. Expression analysis of plasmatic inhibitors from juvenile and adult *B. jararaca***485 **snakes.** The abundance expression of (A) anti-hemorrhagic factor BJ46a (Bj429), (B) γ -486 phospholipase A₂ inhibitor (Bj405), (C) inter-alpha-trypsin inhibitor (Bj203) and (D) plasma

487 protease C1-inhibitor (Bj84). Error bars represent the standard deviation of the mean from three


488 independent experiments (n = 3). Statistical analysis was carried with unpaired *t test*. Asterisks

489 represent significant difference: *p < 0.05 and **p < 0.01. NS = non-statistical significant.



490


491 **Figure 2. Multiple alignments of amino acid sequences of antihemorrhagic factor Bj46a**492 **(Bj429) with similar sequences described in different species of snakes.** The sequences used493 are from *Bothrops jararaca* (sp|Q9DGI0.1), *Protobothrops mucrosquamatus* (XP_015681073.1),494 *Protobothrops flavoviridis* (sp|P29695.2), *Gloydus brevicaudus* (sp|Q5KQS2.1) and *Gloydus*495 *blomhoffii* (sp|Q5KQS1.1). Identical residues are black boxed.



496

497 **Figure 3. Multiple alignments of amino acid sequences of γ - phospholipase A₂ inhibitor**498 **(Bj405) with similar sequences described in different species of snakes. The sequences used**499 are from *Bothrops jararaca* (gb|ABV91331.1), *Protobothrops elegans* (dbj|BAJ14719.1),500 *Bothrops jararacussu* (gb|ABV91333.1), *Bothrops alternatus* (gb|ABV91326.1), *Bothrops*501 *moojeni* (gb|ABV91334.1), *Elaphe climacophora* (dbj|BAH47550.1), *Bothrops neuwiedi*502 (gb|ABV91336.1) and *Bothrops erythromelas* (gb|ABV91328.1). Identical residues are black

503 boxed.



504

505 **Figure 4. Multiple alignments of amino acid sequences of inter-alpha-trypsin inhibitor**506 **(Bj203) with similar sequences described in different species of reptiles. The sequences used**507 **are from *Gekko japonicus* (XP_015262960.1), *Anolis carolinensis* (XP_003217700.2), *Python***508 ***bivittatus* (XP_007442992.1), *Protobothrops mucrosquamatus* (XP_015671353.1), *Pelodiscus***509 ***sinensis* (XP_006127649.1) and from *Chrysemys picta bellii* (XP_008177427.1). Identical**510 **residues are black boxed.**


```

          500      510      520      530      540      550      560
          |.....|.....|.....|.....|.....|.....|.....|.....|.....|
Bj84      -----CGIAPMNQSSCPLVGGKAVLQISEEGVQGA
A. carolinensis  ESIHFKPTIVSLPKFKVDSSQDLTEIIGRMDYGFFFDANICGISPKDLAISSAQHKAVVQISEEGVEAA
P. bivittatus    EAMPLKPTIVTLPKFKLESSQDLSTIIGEMDFGFFFDPDICGITQSKQEVAVSSAKHKAVLQISEEGVEGA
T. sirtalis      EALHVKPTIVMLPKFKLESSQDLAEIIGEMDFGLFYDADICGMTQGELIALSSAKHKSVLQVSEEGVEGA
P. mucrosquamatus KALPLKPTIVTLPKFKLESSQDLAEIIGEMDFGLFYDADICGIAQNEPVVVSSAKHKAVLQISEEGVEGA
A. mississippiensis MGIPFKPTIVLAMPKFKLDSSQDLMAILGEIDYGLFFDANICGISEDEELAVSAAQHRVLEISETGVEAA

          570      580      590      600
          |.....|.....|.....|.....|
Bj84      AATAVSLARLQATMFEVQQPFLEFLIMGGQ-RVEIFLGRVTDPLFF
A. carolinensis  AATSVSLARSANFEVQQPFLEFAVSRDG-KALEFLGRITDPO---
P. bivittatus    AATAVILARLQAAFVQQPFLEFLFLKDN-RVEFLGRVNDPLSL-
T. sirtalis      AATAVNLARLQATVFEVQQPFLEFLVDRDR-RVEVFLGRVTNPLAS-
P. mucrosquamatus AATAVSLARLQATMFEVQQPFLEFLIMGGQ-GVEIFLGRVTDPLAS-
A. mississippiensis AAMAI SVARSALFEVQQPFLEFLVWNDQHGFLEFLGRVNDPSA--

```

512

513 **Figure 5. Multiple alignments of amino acid sequences of plasma protease C1 inhibitor**514 **(Bj84) with similar sequences described in different species of reptiles.** The sequences used515 are from *Anolis carolinensis* (XP_008109235.1), *Python bivittatus* (XP_007423129.1),516 *Thamnophis sirtalis* (XP_013930568.1), *Protobothrops mucrosquamatus* (XP_015676034.1) and517 *Alligator mississippiensis* (gb|KYO40723.1). Identical residues are black boxed.

518 **Table 1. Primers used for qPCR.**

Gene	Primer
β - actin <i>foward</i>	5'-GGCCAACAGAGAGAAGATGACCC-3
β - actin <i>reverse</i>	5'-TCGGTCAAGTCACGGCCA-3'
Bj46a <i>foward</i>	5'-TCAAGAGGGCAGCACAAGAAT-3'
Bj46a <i>reverse</i>	5'-AGTCCGACTCAAACCTGTTCATC -3'
PLI- γ <i>foward</i>	5'-CCAGAAGATGTATGTGGCAAGG -3
PLI- γ <i>reverse</i>	5'-TTTGGTCGGGAGAGGGGC -3'
C1- <i>foward</i>	5'-TCGCTCCAATGAACCAGTCG-3'
C1- <i>reverse</i>	5'-TGACCCGTCCCAGAAAGATTG-3'
Inter-alpha inhibitor <i>foward</i>	5'- CTTACCTCACCATTCACAACCTTCT-3'
Inter-alpha inhibitor <i>reverse</i>	5'- TGGACCCTTGCTGCTTTGC-3'

519